Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/7607
Title: | Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice | Authors: | Sandhu, Geeta Adattini, Josephine Armstrong Gordon, Evangeline O'Neill, Niamh Bagnis, Corrinne Boddy, Alan V Chambers, Pinkie Flynn, Alex Hamilton, Brett Ibrahim, Karim Johnson, David W Karapetis, Christos Kelly, Aisling Kerr, Kimberley-Ann Kichenadasse, Ganessan Kliman, David S Kurkard, Craig Liauw, Winston Lucas, Catherine Mallett, Andrew J Malyszko, Jolanta McCaughan, Georgia Michael, Michael Mirkov, Sanja Morris, Emma Pollock, Carol A Roberts, Darren M Routledge, David J Scuderi, Carla Shingleton, Julia Shortt, Jake Siderov, Jim Sprangers, Ben Stein, Brian N Tey, Amanda Webber, Kate Wichart, Jenny Wong, Rachel Ward, Robyn L |
Issue Date: | 2025 | Source: | Sandhu G, Adattini J, Armstrong Gordon E, O'Neill N, Bagnis C, Boddy AV, Chambers P, Flynn A, Hamilton B, Ibrahim K, Johnson DW, Karapetis C, Kelly A, Kerr KA, Kichenadasse G, Kliman DS, Kurkard C, Liauw W, Lucas C, Mallett AJ, Malyszko J, McCaughan G, Michael M, Mirkov S, Morris E, Pollock CA, Roberts DM, Routledge DJ, Scuderi C, Shingleton J, Shortt J, Siderov J, Sprangers B, Stein BN, Tey A, Webber K, Wichart J, Wong R, Ward RL; ADDIKD Working Group. Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice. EClinicalMedicine. 2025 Mar 25;82:103161. doi: 10.1016/j.eclinm.2025.103161. PMID: 40290844; PMCID: PMC12034076. | Journal Title: | EClinicalMedicine | Journal: | eClinical Medicine | Abstract: | Part 2 of the International Consensus Guideline on Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) offers drug-specific consensus recommendations based on both evidence and practical experience. These recommendations build upon the kidney function assessment and classification guidelines established in Part 1 of ADDIKD. Here we illustrate how dosing recommendations differ between ADDIKD and existing guidance for four commonly used drugs: methotrexate, cisplatin, carboplatin and nivolumab. We then describe how the recommendations can be distilled into practice points for methotrexate and cisplatin. While ADDIKD is a significant improvement from previous guidelines, adoption of this new guideline requires further endorsement from key external stakeholders, 'change championing' by clinicians locally and encouraging its integration into existing reference sources, clinical trial protocols and electronic prescribing systems. Development of the ADDIKD guideline is funded by the NSW Government as part of the Cancer Institute NSW and received no funding from external commercial sources. | Description: | Cairns & Hinterland Hospital and Health Service (CHHHS) affiliated author: Sanja Mirkov | DOI: | 10.1016/j.eclinm.2025.103161 | Keywords: | Chemotherapy;Drug dosing;Kidney dysfunction;Renal;Oncology;Haematology;Pharmacokinetics | Type: | Article |
Appears in Sites: | Cairns & Hinterland HHS Publications Queensland Health Publications |
Show full item record
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.